Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. We then produce the NextGen Bio Class of, twenty companies ranked based on several categories, including Finance, Collaborations, Pipeline, and Innovation. The companies were typically launched no more than 18 months before the list was created.
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Heres a look at the top three companies from the Top 20 Life Science Startups to Watch in 2018.
#1. BlueRock Therapeutics. Founded in 2016, BlueRock was #1 on our list of companies to watch in 2018. With facilities in Ontario, Canada; Cambridge, Massachusetts; and New York, New York, BlueRock launched in December 2016 with a $225 million Series A financing led by Bayer AG and Versant Ventures. The company focuses on cell therapies to regenerate heart muscle in patients who have had a heart attack or chronic heart failure, as well as therapies for patients with Parkinsons disease.
In October 2017, BlueRock and Seattle-based Universal Cells entered into a collaboration and license deal to create induced pluripotent stem (iPS) cell lines that can be used in the manufacture of allogeneic cellular therapies. Shortly afterwards, the company established its corporate headquarters in Cambridge, and in April 2018, established a research-and-development hub in New York City, as well as formalizing a sponsored research collaboration with the Center for Stem Cell Biology at Memorial Sloan Kettering (MSK) Cancer Center. The collaboration focuses on translating Ketterings expertise in creating multiple types of authentic neural cells from stem cells to address diseases of the central and peripheral nervous system. BlueRock also received $1 million from the State of New York and Empire State Development under its economic development initiatives program.
In April 2019, BlueRock partnered with Editas Medicine (which was on BioSpaces NextGen Bio Class of 2015 list) to combine their genome editing and cell therapy technologies to focus on novel engineered cell medicines. Part of the deal was to collaborate on creating novel, allogeneic pluripotent cell lines using a combination of Editas CRISPR genome editing technology and BlueRocks iPSC platform.
And finally, in August 2019, Bayer AG acquired BlueRock for the remaining stake in the company for about $240 million in cash and an additional $360 million in pre-defined development milestones.
#2. Prelude Fertility. Prelude Fertility is a bit of an outlier from the typical BioSpace NextGen company, because it isnt quite a biopharma company. It is a life sciences company whose business model is aimed at in vitro fertilization and egg freezing. It was founded with a $200 million investment by entrepreneur Martin Varsavsky. The investment was in the largest in vitro fertilization clinic in the Southeast, Reproductive Biology Associates of Atlanta, and its affiliate, My Egg Bank, the largest frozen donor egg bank in the U.S.
Since then it has expanded in various parts of the country, including adding San Francisco-based Pacific Fertility Center (PFC) to its network in September 25, 2017; partnering with Houston Fertility Institute and acquiring Vivere Health; partnering with the Advanced Fertility Center of Chicago; and in October 2018, partnered with NYU Langone Health.
In March 2019, Prelude merged with Inception Fertility to establish the Prelude Network as the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in the U.S. Inception is acting as the parent company, with the Prelude Network, both having board representatives from the previous organizations.
#3. Relay Therapeutics. Ranking #3 on our list for 2018, Relay Therapeutics launched in September 2016 with a $57 million Series A financing led by Third Rock Ventures with participation form D.E. Shaw Research. On December 14, 2017, it closed on a Series B round worth $63 million, led by BVF Partners, with new investors GV (formerly Google Ventures), Casdin Capital, EcoR1 Capital and Section 32.
The company focuses on the relationship between protein motion and function. It merges computational power with structural biology, biophysics, chemistry and biology. In December 2018, the company completed a $400 million Series C financing. It was led by the SoftBank Vision fund and included additional new investors, Foresite Capital, Perceptive Advisors and Tavistock Group. Existing investors also participated.
The company announced at the time it planned to use the funds to accelerate the implementation of its long-term strategy, expanding its discovery efforts, advancing existing programs into the clinic and improving its platform.
See the rest here:
Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace
- Asymmetrex Presents the Impact of Differential Stem Cell Counting for Cultured Meat Production - EIN News - October 30th, 2024
- Minor cannabinoid shows promise in reducing anxiety - Drug Discovery News - October 30th, 2024
- Experts call for clear and concise regulation of exosome-based treatments - Medical Xpress - October 27th, 2024
- Stem cells: Arthritic vulture reunited with partner after jab - BBC.com - October 25th, 2024
- Cholesterol medications might be able to be repurposed for MS: Study - Multiple Sclerosis News Today - October 25th, 2024
- Cell and Gene Therapies Symposium Open to Public | Newswise - Newswise - October 25th, 2024
- Could This Protein Hold the Key to Reversing Brain Aging and Repairing Damage? - SciTechDaily - October 24th, 2024
- Arthritic vulture Bernard has his knee fixed in stem cell first - BBC.com - October 24th, 2024
- Findings in fruit flies could lead to new Parkinsons stem cell therapies - Parkinson's News Today - October 24th, 2024
- Stem Cell Therapy Market Size to Hit USD 48.89 Billion by 2033 - GlobeNewswire - October 22nd, 2024
- Japan mulls ways to boost cell, gene therapy approvals - BioWorld Online - October 22nd, 2024
- Meso Numismatics Changes Name to Regenerative Medical Technology Group and Ticker Symbol to RMTG - Newswire - October 22nd, 2024
- Medeze Group Awarded Frost & Sullivan's 2024 Southeast Asia Company of the Year for Delivering Highly Innovative Stem Cell and Longevity Solutions... - October 20th, 2024
- MexStemCells Clinic Partners with PlacidWay Medical Tourism to Expand Global Access to Regenerative Medicine - EIN News - October 20th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - The Conversation - October 18th, 2024
- Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology,... - October 18th, 2024
- Healing begins with research: Promising development program on stem cells in rare diseases - Pharmaceutical Technology - October 15th, 2024
- Chuck Murry | Stem cell science for healing the heart - University of Southern California - October 15th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Medical Xpress - October 15th, 2024
- AI Scaling Laws Poised To Transform Cell Replacement Therapy - Forbes - October 15th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 15th, 2024
- Stem cell discovery highlights importance of DNA methylation in cancer - Medical Xpress - October 11th, 2024
- $8.1M Grant Will Allow Researchers to Study the Ro | Newswise - Newswise - October 11th, 2024
- Crackdowns on Unproven Stem Cell Therapies Worked Abroad - Medpage Today - October 10th, 2024
- Improving Access to Cell and Gene Therapy in Pedia | Newswise - Newswise - October 10th, 2024
- Osteopore Partners with RxCell for Regenerative Medicine - TipRanks - October 10th, 2024
- USC's Keck School of Medicine partners with StemCardia to advance heart failure treatment - News-Medical.Net - October 10th, 2024
- Dr. Abdul Baker Pioneers Robotic Surgery and Stem Cell Therapy for Innovative Treatment & Recovery - openPR - October 8th, 2024
- How a Court Ruling Affects California Stem Cell Clinics That Use Unproven Therapies - KQED - October 8th, 2024
- Stem-cell therapy reverses type 1 diabetes in groundbreaking case study - Medical News Today - October 4th, 2024
- Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in... - October 4th, 2024
- Stem cell therapy to cure T1 diabetes? The Indian perspective - The Hindu - October 4th, 2024
- Stem cell therapy for osteoarthritis: Functional cartilage regeneration using 3d bioprinting technology - Open Access Government - October 4th, 2024
- Innovative Opportunities in Stem Cell Treatments: Insights from Genoma - Medical Tourism Magazine - October 4th, 2024
- BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - Yahoo Finance - October 4th, 2024
- Palmetto Stem Cell Therapy Advises on Streamlining the Regenerative Medicine Process for Joint Pain Relief - The Globe and Mail - October 2nd, 2024
- Woman's Own Stem Cells Appear to Reverse Her Type 1 Diabetes in First-Ever Procedure - Futurism - October 2nd, 2024
- Cell & Co. is Revolutionizing Regenerative Healthcare with Cutting-Edge Stem Cell Therapy in Malaysia - openPR - October 2nd, 2024
- Neanderthoids and space brains: Stem cell researcher pushes the boundaries of neuroscience - MSN - October 2nd, 2024
- What are Exosomes, Growth Factors and Stem Cells? - NewBeauty Magazine - September 30th, 2024
- Treatment - National Heart, Lung, and Blood Institute - September 30th, 2024
- Neanderthoids and space brains: Stem cell researcher pushes the boundaries of neuroscience - Medical Xpress - September 30th, 2024
- Stem Cell Therapy Market Overview, Share Analysis, Size And Forecast To 2033 - WhaTech - September 30th, 2024
- StemCardia Licenses Technologies for Heart Regeneration Developed at UW School of Medicine - Business Wire - September 30th, 2024
- Chinese Woman Becomes First In The World To Be Cured Of Type 1 Diabetes With Stem Cell Transplant - GreekCityTimes.com - September 30th, 2024
- Following Their Calling to Help Young Cancer Patients and Beyond - Stanford Children's Health - September 28th, 2024
- Greenberg Regenerative Medicine Celebrates Nearing 2 Years of Success with Pioneering VSEL Therapy - PR.com - September 28th, 2024
- Discovery clears hurdle in growing organs for transplants : Newsroom - UT Southwestern - September 26th, 2024
- Cell Therapy Market is Expected to Gain USD 60696.42 Million with a Growing CAGR of 19.20% by 2030 - openPR - September 25th, 2024
- Stem Cell Therapy Market To Reach USD 44 Billion By 2032 (Updated 2024) - Market.us Media - United States Market News - September 25th, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 23rd, 2024
- The new frontier of luxury travel is a $44,000 course of stem cells and a longevity club stocked with IV stations - Fortune - September 23rd, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 20th, 2024
- Exploring Regenerative Medicine and Its Impact on Modern Disease Management - Baltimore Post-Examiner - September 18th, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 16th, 2024
- Stem Cell Restore Review: Can It Boost Your Stem Cell Activity for Lasting Health? - Vashon-Maury Island Beachcomber - September 14th, 2024
- Stem Cell Therapy Market valued at USD 3.40 Billion by 2030 As Revealed In New Report - WhaTech - September 14th, 2024
- Stem Cell Manufacturing Market Projected to Witness Huge Growth by 2024-2031 As Revealed In New Report - WhaTech - September 14th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 12th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - StockTitan - September 10th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - Newswire - September 10th, 2024
- Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure - News-Medical.Net - September 8th, 2024
- Stem Cell Therapy Market Is Estimated To Reach $928.6 Million by 2031 | CAGR 16.2% - EIN News - September 8th, 2024
- USC researchers receive funding to develop next generation of intelligent biocomputers - EurekAlert - September 8th, 2024
- Risk Factors and Indications for Stem Cell Transplants in MDS - Targeted Oncology - September 6th, 2024
- Cell Therapy Market Size to Hit USD 28.98 Billion by 2032, - GlobeNewswire - September 6th, 2024
- Blood stem cells grown in the lab for the first time ever - Earth.com - September 6th, 2024
- Top 3 Grants in Regenerative Medicine: August 2024 - RegMedNet - September 6th, 2024
- New approach moves cell therapy closer to treating many disorders - Medical Xpress - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- What Sets Immunotherapy Regenerative Medicine Apart in a Crowded Regenerative Market? - Flaunt Magazine - September 2nd, 2024
- Tiny Test Tubes Sort Stem Cells for Improved Therapy - The Scientist - August 31st, 2024
- Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax - August 31st, 2024
- From stem cells to technology, the next Wisconsin RISE initiative focuses on improving health - University of Wisconsin-Madison - August 29th, 2024
- aHSCT Stem Cell Therapy for MS | National MS Society - National MS Society - August 29th, 2024
- Are Stem Cells the Secret to Anti-Aging? - The Edge - August 22nd, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
- Scientists discover method to activate dormant stem cells in the brain - Medical Xpress - August 20th, 2024
- New way to extend 'shelf life' of blood stem cells can improve gene therapy - Medical Xpress - August 20th, 2024
- Where Are the Cell Therapies for Type 1 Diabetes? - Inside Precision Medicine - August 14th, 2024
Recent Comments